Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Cryotherapy and Tirbanibulin for Actinic Keratosis in Organ Transplant Patients

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of actinic keratosis, a skin condition that often appears as rough, scaly patches on the skin due to long-term sun exposure. The study involves patients who have received a solid organ transplant. The treatment being tested is a combination of cryotherapy, which is a method that uses extreme cold to destroy abnormal tissue, and a topical ointment called tirbanibulin (known by the brand name Klisyri 10 mg/g ointment). The purpose of the study is to evaluate how effective this combination treatment is for reducing the number of actinic keratosis lesions in these patients.

Participants in the study will receive treatment on two symmetrical areas of their skin. One area will be treated with both cryotherapy and tirbanibulin, while the other area will receive only cryotherapy. This will help researchers compare the effectiveness of the combination treatment against cryotherapy alone. The study will monitor changes in the number of actinic keratosis lesions over a period of three months. Researchers will also observe any skin reactions and assess the patients' quality of life and satisfaction with the treatment.

The study aims to provide valuable information on whether the addition of tirbanibulin to cryotherapy offers better results for patients with actinic keratosis who have undergone organ transplants. By understanding the potential benefits and any side effects, this research could lead to improved treatment options for managing this skin condition in transplant recipients.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient must meet specific criteria, including being a solid organ transplant recipient with actinic keratosis (AK), having stable immunosuppressive treatment for at least six months, and having 4 to 8 AKs in two symmetrical areas of 25 cm².

    The patient must be at least 18 years old and have given consent to participate. Women of childbearing potential must use a safe means of contraception during the treatment period and for at least one month afterward.

  2. Step 2

    Initial treatment phase

    The treatment involves two phases. Initially, cryotherapy is applied to the affected areas. Cryotherapy is a procedure that uses extreme cold to destroy abnormal tissue.

  3. Step 3

    Application of tirbanibulin ointment

    Following cryotherapy, the patient applies Klisyri 10 mg/g ointment, which contains the active substance tirbanibulin, to the treated areas. This ointment is used for cutaneous application, meaning it is applied directly to the skin.

    The ointment is applied once daily for five consecutive days.

  4. Step 4

    Follow-up and assessment

    The primary goal is to evaluate the percentage change in the number of AKs on the side treated with both cryotherapy and tirbanibulin after three months, compared to the side treated with cryotherapy alone.

    Secondary assessments include the percentage of patients with a complete or partial response in lesion reduction, the number of new and persistent AKs, local skin reactions, treatment tolerance, and differences in quality of life scales.

  5. Step 5

    Completion of the trial

    The trial is expected to conclude by December 16, 2024. The patient's progress and response to treatment will be monitored throughout the study period.

Who can join the trial?

9 criteria

  • Must be a patient who has had a **solid organ transplant**. This means you have received an organ like a kidney, liver, or heart from a donor.
  • Must have **actinic keratosis (AK)**, which are rough, scaly patches on the skin caused by sun exposure.
  • At least one year must have passed since your organ transplant.
  • Your **immunosuppressive treatment** should be stable for at least 6 months. This is the medication you take to prevent your body from rejecting the transplanted organ.
  • You should have between 4 to 8 actinic keratoses in two symmetrical areas of 25 square centimeters, either on the face or scalp, that can be treated.
  • You must be 18 years old or older.
  • You, or your representative, must agree to participate in the study by giving consent.
  • The study investigator must believe you can follow all the study requirements.
  • If you are a woman who can have children, you must agree to use a reliable form of **contraception** during the study and for at least one month after. Abstinence is considered an acceptable method. A negative pregnancy test is required at the start of the study.

Who cannot join the trial?

4 criteria

  • Patients who do not have actinic keratosis, which are rough, scaly patches on the skin caused by sun damage, cannot participate.
  • Patients who are not solid organ transplant recipients cannot participate. Solid organ transplant refers to receiving an organ like a kidney, liver, or heart from a donor.
  • Patients who are under the age of 18 or over the age of 65 cannot participate.
  • Patients who are part of a vulnerable population, meaning they might need special protection or care, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Cryotherapy

    is a treatment that uses extreme cold to freeze and destroy abnormal skin cells. In this trial, it is used as the first step in a sequential therapy to treat actinic keratosis, which are rough, scaly patches on the skin caused by sun damage. Cryotherapy helps to remove these damaged cells, making it an effective initial treatment for this condition.

  • Tirbanibulin

    is a topical medication applied directly to the skin. It is used in this trial as the second step in the sequential therapy following cryotherapy. Tirbanibulin works by stopping the growth of abnormal cells, helping to clear actinic keratosis lesions. This medication is particularly useful for patients who have undergone organ transplants, as it helps manage skin conditions that can arise due to their immunosuppressed state.

What is already known about the treatment

Tirbanibulin – Tirbanibulin is administered topically as a 1% ointment, applied directly to the skin. It is currently being studied in clinical trials for its effectiveness in treating actinic keratosis, particularly in patients who have undergone organ transplants. The medication works by inhibiting specific proteins involved in cell growth, thereby reducing abnormal skin cell proliferation. Tirbanibulin is classified as a microtubule inhibitor, which interferes with the cellular structures necessary for cell division.

Investigated diseases

Actinic keratosis – Actinic keratosis is a skin condition characterized by rough, scaly patches on the skin, primarily caused by prolonged exposure to the sun. These patches are often found on areas such as the face, ears, neck, scalp, chest, backs of the hands, forearms, or lips. The condition progresses slowly and can vary in appearance, sometimes being red, pink, or brown. Over time, the patches may become thicker and more pronounced. Actinic keratosis is considered a precancerous condition, as it can potentially develop into skin cancer if left untreated. It is more common in fair-skinned individuals and those with a history of sunburns or extensive sun exposure.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-508091-11-00Protocol codeTIRTRASPEstimated enrolment40 patientsSponsorClinica Universidad De Navarra

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).